Semaglutide
A Study of BGM0504 in Early T2DM With Obesity
Novo Nordisk · Phase 3 · Recruiting · Enrollment 372
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| BGM0504 Injection 15 mg | n/r | n/r | n/r | n/r | n/r |
| Semaglutide Injection 1.0 mg | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.